Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension

Minerva Cardioangiologica

Volumn 50, Issue 3, 2002, Pages 169-174

  Palmieri, V ^a,b   Devereux, R B ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Antihypertensive agents; Hypertension, drug therapy; Hypertrophy, left ventricular

Indexed keywords

ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; NIFEDIPINE; 1,4 DIHYDROPYRIDINE; 1,4-DIHYDROPYRIDINE; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG EFFICACY; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERTENSION; PROGNOSIS; REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE MODEL; DRUG COMBINATION; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; META ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TIME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMAL; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CALCIUM CHANNEL BLOCKERS; COMPARATIVE STUDY; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DIURETICS, THIAZIDE; DRUG THERAPY, COMBINATION; ENALAPRIL; FOLLOW-UP STUDIES; HUMAN; HYDROCHLOROTHIAZIDE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; META-ANALYSIS; NIFEDIPINE; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RATS; RATS, INBRED SHR; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; ANIMALS; DIURETICS; HUMANS; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 0036024075     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Casale PN, Devereux RB, Kligfield P, Eisenberg RR, Miller DH, Chaudhary BS et al. Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol 1985;6:572-80.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
3. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
4. Gottdiener JS, Arnold AM, Aurigemma GP, Polak JF, Tracy RP, Kitzman DW et al. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000;35:1628-37.
5. Muiesan ML, Salvetti M, Rizzoni D, Castellano M. Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995;13:1091-5.
6. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998;97:48-54.
7. Devereux RB, Agabiti-Rosei E, Dahlof B, Gosse P, Hahn RT, Okin PM et al. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials [erratum in J Hypertens 1997;15:103]. J Hypertens 1996;14:S95-101.
8. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure [erratum in Arch Intern Med 1998;158(6):573]. Arch Intern Med 1997;157:2413-46.
9. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5:95-110.
10. Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertensive agents. Am J Hypertens 1998;11:1394-404.
11. Murdoch D, Brogden RN. Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders. Drugs 1991;41:737-79.
12. Devereux RB, Roman MJ, de Simone G, O'Grady MJ, Paranicas M, Yeh JL et al. Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. Circulation 1997;96:1416-23.
13. Bella JN, Devereux RB, Roman MJ. O'Grady MJ, Welty TK, Lee ET et al. Relations of left ventricular mass to fat-free and adipose body mass. The Strong Heart Study Investigators. Circulation 1998;98:2538-44.
14. Palmieri V, de Simone G, Arnett DK. Bella JN, Kitzman DW, Oberman A et al. Relation of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). Am J Cardiol 2001;88:1163-8.
15. Devereux RB, Roman MJ. Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Hypertens Res 1999;22:1-9.
16. Pfeffer JM, Pfeffer MA, Fishbein MC, Frohlich ED. Cardiac function and morphology with aging in the spontaneously hypertensive rat. Am J Physiol 1979;237: H461-8.
17. Thiedemann KU, Holubarsch C, Medugorac I, Jacob R. Connective tissue content and myocardial stiffness in pressure overload hypertrophy. A combined study of morphologic, morphometric, biochemical, and mechanical parameters. Basic Res Cardiol 1983;78:140-55.
18. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64.
19. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin- angiotensin-aldosterone system. Circulation 1991;83:1849-65.
20. Brilla CG, Matsupara LS, Weber KT Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75.
21. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OH. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat Circulation 1995;91:161-70.
22. Gardin JM, Siscovick D, Anton-Culver H, Lynch JC, Smith VE, Klopfenstein HS et al. Sex, age, and disease affect echocardiographic left ventricular mass and systolic function in the free-living elderly. The Cardiovascular Health Study. Circulation 1995;91:1739-48.
23. Palmieri V, Bella N, DeQuattro V, Roman MJ, Hahn RT, Dahlof B et al. Relations of diastotic left ventricular filling to systolic chamber and myocardial contractility in hypertensive patients with left ventricular hypertrophy (The PRESERVE Study). Am J Cardiol 1999;84: 558-62.
24. de Simone G, Greco R, Mureddu G, Romano C, Guida R, Celentano A et al. Relation of left ventricular diastolic properties to systolic function in arterial hypertension. Circulation 2000 101:152-7.
25. Bella JN, Palmieri V, Liu JE, Kitzman DW, Oberman A, Hunt SC et al. Relationship between left ventricular diastolic relaxation and systolic function in hypertension: The Hypertension Genetic Epidemiology Network (HyperGEN) Study. Hypertension 2001;38:424-8.
26. Wachtell K, Smith G, Gerdts E, Dahlof B, Nieminen MS, Papademetr ou V et al. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan intervention For Endpoint. Am J Cardiol 2000;85: 466-72.
27. Wachtell K, Rokkedal J, Bella JN, Aalto T, Dahlof B, Smith G et al. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint. Am J Cardiol 2001;87:54-60.
28. Nishimura RA, Housmans PR, Hatle LK, Tajik AJ. Assessment of diastolic function of the heart: background and current applications of Doppler echocardiography. Part I. Physiologic and pathophysiologic features. Mayo Clin Proc 1989;64:71-81.
29. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991;69:107-15.
30. Brilla CG. Structural basis of LV dysfunction: collagen matrix remodelling and the renin-angiotensin-aldosterone system. Int J Clin Pract Suppl 1999;108:14-6.
31. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med 1992;117:502-10.
32. Vasan RS, Benjamin EJ, Levy D. Congestive heart failure with normal left ventricular systolic function. Clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med 1996;156:146-57.
33. Devereux RB, Roman MJ, Liu JE, Welty TK, Lee ET, Rodeheffer R et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol 2000;86:1090-6
34. Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001;344:17-22.
35. Aurigemma GP, Gottdiener JS, Shemanski L, Gardin J, Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2001;37:1042-8.
36. Chapman D, Weber KT, Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res 1990;67:787-94.
37. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-20.
38. Celentano A, Mancini FP, Crivaro M, Palmieri V, Ferrara LA, De Stefano V et al. Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. Am J Cardiol 1999;83:1196-200.
39. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991;83:1771-9.
40. Dahlof B, Hansson L. Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. J Hypertens 1992;10:1513-24.
41. Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997;95:2007-14.
42. Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE et al. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. AmJ Hypertens 1998;11:387-96.
43. Papademetriou V, Gottdiener JS, Narayan P, Cushman WG, Zachariah PK, Gottdiener PS et al. Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial. The Isradipine Study Group. J Am Coll Cardiol 1997;30: 1802-8.
44. Devereux RB, Dahlof B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol 1996;78:61-5.
45. Palmieri V, Dahlöf B, DeQuattro V, Sharpe N, Bella JN, de Simone G et al. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. J Am Coll Cardiol 1999;34: 1625-32.
46. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation 2001;104:1248-54.
47. Fagard RH. Reversibility of left ventricular hypertrophy by antihypertensive drags. Neth J Med 1995;47: 173-9.
48. Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 1998;13:564-9.
49. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993;270:713-24.
50. Midrvedt K, Ihlen H, Hartmann A, Bryde P, Bjerkely BL, Foss A et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 2001;72:107-11.
51. Sharifi AM, LiJS, Endemann D, Schiffrin EL. Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 1998;16: 457-66.
52. Devereux RB, Palmieri V, Wachtell K, Bella JN, Boman K, Gerdts E et al. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the LIFE study. J Hypertens 2002, in press.
53. Lees KR, Reid JL. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clin Pharmacol Ther 1987;41:597-602.
54. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990;16:564-72.
55. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997;336:1350-5.
56. Palmieri V, Wachtell K, Gerdts E, Bella JN, Papademetriou V, Tuxen C et al. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE Study. Am Heart J 2001;141:784-91.
57. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388-93.
58. Diez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995;91:1450-6.